Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024)
Alto Neuroscience's (ANRO) quarterly Total Non-Current Liabilities came in at $26.1 million in Q4 2024, up 68.59% year-on-year from $15.5 million in Q1 2024, and down 1.78% quarter-over-quarter from $26.6 million in Q3 2024.
Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Alto Neuroscience has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $26.1 million for Q4 2024.
- Total Non-Current Liabilities for Q4 2024 came in at $26.1 million, up 68.59% year-over-year; the trailing twelve-month figure through Dec 2024 was $26.1 million (up 68.59% YoY), and the FY2024 annual result was $26.1 million, up 68.59% from the prior year.
- Total Non-Current Liabilities came in at $26.1 million for Q4 2024 at Alto Neuroscience, down from $26.6 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $59.7 million in Q3 2023 to a low of $15.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 26.08 Mn |
| Sep 30, 2024 | 26.56 Mn |
| Jun 30, 2024 | 17.58 Mn |
| Mar 31, 2024 | 16.82 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Sep 30, 2023 | 59.70 Mn |
| Jun 30, 2023 | 51.00 Mn |
| Mar 31, 2023 | 43.53 Mn |